



Renal tumours in a Tsc2+/- mouse model do not show feedback inhibition of Akt and are 
effectively prevented by rapamycin   
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Tuberous sclerosis (TSC) is an inherited syndrome in which tumours in multiple organs are 
characterised by activation of mammalian target of rapamycin complex 1 (mTORC1). 
Previous work suggests that mTORC1 activation is associated with feedback inhibition of 
Akt, a substrate of mammalian target of rapamycin complex 2 (mTORC2). This could limit 
TSC-associated tumour growth but lead to paradoxical promotion of tumour cell survival 
upon treatment with mTOR inhibitors. However, Akt/mTOR signalling has not been fully 
investigated in TSC-associated tumours and it has been uncertain whether mTOR inhibition 
can prevent TSC-associated renal tumourigenesis. In this study, we investigated Akt/mTOR 
signalling in renal tumours using a Tsc2+/- mouse model and tested whether mTOR inhibition 
could prevent renal tumourigenesis.  We found that all renal lesions including cysts, 
adenomas and carcinomas exhibited activation of both Akt and mTORC1 as evidenced by 
increased protein expression and phosphorylation of Akt and mTOR and their downstream 
targets. PKCα was also highly expressed and phosphorylated in these lesions, consistent with 
activation of mTORC2. Surprisingly, IRS proteins were highly expressed, in contrast to a 
striking decrease seen in cultured Tsc2-/- mouse embryonic fibroblasts, suggesting one 
mechanism through which loss of feedback inhibition of Akt may occur in mTORC1 
hyperactivated Tsc-associated tumours. Long term treatment with rapamycin reduced both 
Akt and mTORC1 activity in normal kidney tissues and blocked the development of all types 
of renal lesions.  In conclusion, in contrast to previous studies, we found that Akt signalling is 
not inhibited in Tsc-associated renal lesions and that by partially inhibiting the Akt/mTOR 
pathway, rapamycin is highly effective in preventing Tsc-associated tumours. 





The Akt kinase family integrates many cell signals, modulates multiple cellular activities and 
has a large number of molecular targets and effectors (1). The serine/threonine kinase mTOR 
is associated with two distinct multi-protein complexes (mTORC1 and mTORC2) and acts 
downstream of PI3K/Akt to regulate cellular processes such as metabolism, growth, 
proliferation, survival, differentiation, self-renewal, autophagy and apoptosis (2-4). Many 
components of the PI3K/AKT/mTOR signalling pathway are mutated in human cancers (5-
7). Several upstream negative regulators of mTOR are tumour suppressors and are mutated in 
inherited tumour syndromes including tuberous sclerosis (TSC) (8-13).  TSC is caused by 
mutations of TSC1 or TSC2 and characterised by development of tumours in many organs. 
Kidney tumours termed angiomyolipomas (AMLs) are among its most frequent 
manifestations and lead to significant morbidity and mortality due to haemorrhage and kidney 
failure. The TSC1 and TSC2 proteins form a complex that down-regulates mTOR activity 
and TSC-associated tumours show aberrant activation of mTOR signalling in both patients 
and animal models.  
      In mouse embryonic fibroblasts (MEF) lacking Tsc1 or Tsc2, Akt signalling is inhibited 
by a negative feedback loop (14, 15). In these cells, mTOR activates p70 S6 kinase (S6K) 
that inhibits Akt activity by direct phosphorylation of IRS1 and by repressing IRS1 gene 
expression (16). IRS2 is also down-regulated by mTOR activation (16, 17). More recently, 
Grb10, the growth factor receptor–bound protein 10, has been identified as a substrate of 
mTORC1 that also negatively regulates PI3K/Akt activity in Tsc1 or Tsc2 null MEF cells 
(18, 19).  These cells have reduced tumorigenic potential while myr-Akt–expressing Tsc2–/– 
MEF cells demonstrate accelerated tumour growth in nude mice (20).  Feedback inhibition of 
Akt signalling has been reported to limit the growth of tumours in the liver of a Tsc2+/- mouse 
model (21). These results suggest that feedback inhibition of Akt signaling in cells with no 
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functional TSC1 or TSC2 might contribute to the low malignant potential of tumours in TSC 
patients. In contrast to the usually benign features of renal AMLs in human TSC, Tsc1+/- or 
Tsc2+/- mice develop frequent renal cell carcinomas (22, 23). It remains to be fully assessed 
whether negative feedback on Akt signalling occurs in these tumours.   
  
    The mTOR inhibitor rapamycin and its analogues (rapalogs) have been used to treat a 
variety of human cancers as well as patients with TSC. TSC-associated tumours including 
AMLs and subependymal giant cell astrocytomas (SEGA) exhibit consistent but partial and 
reversible responses to rapamycin and the rapalog everolimus (24-27). As yet, no properly 
designed studies have investigated whether these drugs can prevent tumourigenesis in TSC 
patients or animal models. 
     In this study, we examined Akt/mTOR signalling in renal lesions and corresponding 
normal kidney tissues using a Tsc2+/- mouse model. We also tested the efficacy of rapamycin 
for prevention of renal tumours and its effect on Akt/mTOR signalling. In contrast to 
previous studies, we found that feedback inhibition of Akt signalling was not seen in renal 
lesions of Tsc2+/- mice. We also found that rapamycin was highly effective in preventing 
tumour development. 
RESULTS 
Renal Lesions in Tsc2+/- mice show loss of Tsc2 and hyperactivation of mTORC1 
signalling 
Histology and immunohistochemistry (IHC) were used to analyse spontaneously arising renal 
lesions in both kidneys of 15 Tsc2+/- mice at the age of 10 months. These lesions included 
microscopic dysplastic lesions (renal intraepithelial neoplasias or RINs), cysts, papillary and 
solid adenomas, and carcinomas (Supplemental Figure 1), and were highly proliferative 
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(Supplemental Figure 2). By IHC, we found that  91.1 % (123/135) of renal lesions had no 
detectable Tsc2, 8.2 % (11/135) had markedly reduced expression and only one cyst out of 
135 lesions had an increased expression of Tsc2 compared to neighbouring kidney tissues 
(Figure 1; Supplemental Table 1). By PCR, loss of heterozygocity (LOH) of Tsc2 was 
observed in 3 of 4 renal tumours tested (Figures 2c and 3c). By Western blot, little Tsc2 
expression was detected in tumours with LOH (Figures 2c and 3c). No LOH was detected in 
tumour 4 but Tsc2 expression was substantially reduced, suggesting an alternative 
mechanism affecting the wild type allele such as an intragenic mutation or epigenetic 
suppression (Figures 2c and 3c).    
    As expected, increased protein levels of mTOR and its downstream signalling components 
S6K and S6 ribosomal protein (S6) were observed in all renal lesions (Figure 2a, b and c). 
Hyper-activation of mTOR was evidenced by increased phosphorylation of mTOR at S2448 
and S2481 as well as increased phosphorylation of its major effectors S6K at T389, S6 at 
S235/236, and 4EBP1 at T37/46, S65 and T70 (Figure 2a, b and c, Supplemental Figure 3). 
These results indicated that in the majority of renal tumours of Tsc2+/- mice Tsc2 was lost 
leading to aberrant activation of mTOR/S6K signalling.  
Akt activity is not inhibited in renal lesions of Tsc2+/- mice 
We re-examined the previously reported suppression of Akt signalling in cultured Tsc1 or 
Tsc2 deficient cells (Supplemental Figure 4). As expected, immortalised TP53-/-Tsc2-/- MEF 
cells showed mTOR activation but reduced Akt activity compared to control TP53-/-Tsc2+/+ 
MEF cells. Similarly, though less pronounced, changes were seen in non-immortalised Tsc1-/- 
MEF cells (Supplemental Figure 4).      
    We then used IHC and Western blot to investigate Akt signalling in renal lesions of Tsc2+/- 
mice. All lesions showed an increased level of total Akt compared to adjacent normal kidney 
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tissues (Figure 3a and c). Levels of Akt1, Akt2 and Akt3 were all increased in tumours 
(Figure 3c). Since Akt is fully activated by phosphorylation of the activation loop at T308 
and the hydrophobic motif at S473, and stabilised by phosphorylation of the turn motif at 
T450, we then examined the phosphorylation levels at these sites. In contrast to the findings 
in cultured MEFs, elevated phosphorylation of Akt at S473 and at T450 as well as Akt1 at 
S473 was evident in all lesions (Figures 3a, c and Supplemental Figure 3). Phosphorylation of 
Akt at T308 was also present in a proportion of tumour cells in renal lesions (Figure 3a and 
c). Expression of the Akt targets HIF1α and GLUT1 was increased, and increased 
phosphorylation of an array of well characterised Akt substrates was observed including 
eNOS, MDM2, GSK3α, GSK3β, IKKα, RAF1and FOXO1A (Figure 3b  and c; Supplemental 
Figures 3 and 5). Of note, higher expression of both β-actin and GAPDH was observed in 
tumour cells than adjacent normal kidney tissues (Supplemental Figure 6). Therefore, relative 
protein and phosphorylation levels of Akt/mTOR signalling components in tumour samples 
might be underestimated on Western blot analysis.  
    mTORC2 specifically phosphorylates the hydrophobic motif and turn motif sites of Akt at 
S473 and T450 (28, 29).  We therefore speculated that other mTORC2 substrates such as 
PKCα, another AGC kinase family member, may also be highly phosphorylated at similar 
sites in Tsc-associated tumours. We examined the expression and phosphorylation of PKCα 
in renal lesions of Tsc2+/-mice by IHC and Western blot. All renal lesions examined had 
increased expression and phosphorylation of PKCα at T638 and S657 (Figure 4).  
    mTOR also negatively regulates PI3K/Akt by reducing expression of PDGFRs (20). We 
found that PDGFRβ expression was reduced in renal lesions but expression and 
phosphorylation of Erk1/2, another downstream target of PDGFRs, were increased, 
indicating activation of the MAPK pathway, again in contrast to Tsc2 null MEFs (Figure 5, 
Supplemental Figure 7).  These data demonstrate that Akt, PKCα and the MAPK pathway are 
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not inhibited in renal lesions of Tsc2+/- mice despite hyper-activation of mTOR/S6K 
signalling.     
IRS protein levels are increased in renal tumours of Tsc2+/- mice 
To investigate the mechanisms through which negative feedback inhibition of Akt is lost in 
Tsc-associated renal tumours, we used Western blot, IHC and quantitative real time PCR (q-
PCR) to assess components of the feedback loop. We found that expression of both insulin 
receptor (IR) and IGF1 receptor (IGF1R) was reduced in renal tumours (Figure 5 and 6). 
Phosphorylation of IGF1R at Y1135/1136 (IR at Y1150/1151) was also reduced (Figure 5). 
Similar findings were obtained from Tsc2 null MEFs (Figure 5).  However, unlike Tsc2 null 
MEFs, tumours had increased levels of IRS proteins and slightly reduced expression of 
Grb10 protein (Figures 5 and 6). Phosphorylation of numerous serine residues of these 
proteins is regulated by mTOR and sensitive to rapamycin  (supplementary Figure 8). In both 
renal tumours and MEFs, IRS, IRS2 and Grb10 were highly phosphorylated at S302, 
S731and S476 respectively (Figures 5 and 6). However, very little phosphorylation at 
S501/503 was detected by Western blot in normal kidneys or renal tumours (Figures 5), and 
only slightly increased phosphorylation at these sites was detected by IHC in these tumours 
(Supplemental Figure 9). Finally, transcription of IGF1R, IRS1 and IRS2 was suppressed in 
renal tumours although to a less extent as observed in Tsc2 null MEFs (Supplemental 10). 
These findings suggest that increased levels of IRS proteins might result from increased 
protein stabilisation and were in agreement with the observed activation of Akt signalling in 
renal tumours of Tsc2+/- mice.         




Kidney tissues from 4 pairs of litter-mate Tsc2+/- mice treated for 6 weeks with rapamycin or 
vehicle were used for Western blot. Phosphorylation of Akt at S473 and its targets GSK3β at 
S9, eNOS at S1177 and MDM2 at S166 was reduced in kidney tissues of rapamycin treated 
mice compared to their vehicle treated litter mates (Figure 7). Phosphorylation of mTOR at 
S2448 and S2481, and S6 at S235/236 was also decreased in kidney tissues of rapamycin 
treated mice compared to their vehicle treated litter mates (Figure 7).  Band shift in total 
4EBP1 was observed indicating reduced phosphorylation in kidney tissues of rapamycin 
treated mice compared to their vehicle treated litter mates.  No consistent increase or decrease 
in phosphorylation of Akt at T308 was detected in kidney tissues of rapamycin treated mice 
compared to their vehicle treated litter mates. Thus, rather than promoting Akt activity, 
rapamycin inhibited both Akt and mTORC1 in normal kidney tissues of Tsc2+/- mice.  
Rapamycin effectively blocks tumourigenesis in the kidneys of Tsc2+/- mice by inhibiting 
Akt/mTOR signaling 
To test whether rapamycin could prevent tumourigenesis in the kidneys of Tsc2+/- mice, we 
first established the earliest age at which renal lesions developed on the balb/c genetic 
background. We examined by microscopy H&E stained consecutive 5 µm kidney sections 
from 6 mice at each of the following ages: 15 days, 30 days, 45 days and 60 days.  Only at 60 
days of age were microscopic dysplastic lesions (RINs) seen together with microscopic cysts. 
We next randomly allocated litter-mate Tsc2+/- mice with balanced gender into two groups: 
rapamycin (n=20) and vehicle (n=20) (Supplemental Table 2). Treatment was commenced 
with rapamycin or vehicle at 1 month of age and continued until mice were sacrificed. Half of 
each group was sacrificed at 8 months and the remainder at 10 months. One mouse in the 
rapamycin treatment group died unexpectedly before the end of the experiment. No gross or 
microscopic renal lesions were found in this mouse but it was excluded from further analysis 
in this study. Analysis of renal pathology was carried out by a scientist and by a renal 
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pathologist both blinded to treatment status. Full coronal histological sections were taken at 
200 µM intervals from every kidney. All macroscopically and microscopically observed 
lesions were counted, characterised and quantified by measuring both their maximum cross-
sectional areas (lesion size) and also the areas representing only their cellular components, as 
described previously (30). The vehicle treated mice all had multiple bilateral renal lesions 
including RINs, cystic, papillary and solid lesions. By contrast, of 9 mice treated with 
rapamycin and sacrificed at  8 months only one showed 2 microscopic cysts (P < 0.0001) and 
no lesions were seen in any of 10 mice sacrificed at 10 months (P < 0.0001, Figure 8a; 
Supplemental Table 3). Thus rapamycin was highly effective in blocking tumourigenesis in 
the kidneys of Tsc2+/- mice.    
    We then examined the effect of long term treatment with rapamycin on Akt/mTOR 
signalling in the kidneys of Tsc2+/- mice. Kidney sections prepared from mice sacrificed at 10 
months following treatment with rapamycin or vehicle were used for IHC. mTORC1 
signalling appeared to be attenuated in rapamycin treated kidney tissues as indicated by 
reduced phosphorylation of  S6 at S235/236 and 4EBP1 at S65 (Figure 8b).  Akt signalling 
was also suppressed in rapamycin treated kidney tissues as indicated by reduced 
phosphorylation of Akt at S473 and its targets eNOS at S1177 and MDM2 at S166 although 
phosphorylation of Akt at T308 was variable in both rapamycin and vehicle treated tissues 
(Figure 8b).  
DISCUSSION 
We have investigated Akt/mTOR signalling in normal kidney tissues and renal lesions of a 
Tsc2+/- mouse model. We have demonstrated that feedback inhibition of Akt signalling 
appears to be lost in Tsc2-associated renal tumours that are characterised by activation of 
mTORC1. Our findings are unexpected because in MEF cells lacking either Tsc1 or Tsc2 Akt 
signalling is inhibited via a negative feedback loop elicited by activated mTOR/S6K 
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signalling (14, 15). Furthermore, based upon IHC-determined cytoplasmic and nuclear 
localization of FOXO1, feedback inhibition of Akt signalling was reported previously to be 
operating in liver hemangiomas in Tsc2+/- mice (21). Decreased phosphorylation of Akt at 
S473 detected by IHC has also indicated the existence of negative feedback on Akt signalling 
in human TSC-associated renal AMLs (31). In contrast, in Tsc2+/- mouse tumours, we found 
that FOXO1 was highly phosphorylated at S256, a specific Akt target site, and located in 
both the cytoplasm and the nucleus. Notably, we found that Akt was highly phosphorylated at 
S473 in all Tsc-associated tumours. Increased phosphorylation of multiple effectors of Akt 
was also observed in these tumours. To confirm these findings we used at least two different 
antibodies against each protein with two different IHC protocols (unpublished observations). 
Furthermore, the IHC data were entirely consistent with the findings of Western blot 
analyses. 
 
    Since Akt is specifically phosphorylated at T450 and S473 by mTORC2 (28, 29), our 
results suggested that mTORC2 was activated in Tsc2+/- mouse renal tumours.  Consistent 
with this but in contrast to a previously published report (31), PKCα, another mTORC2 
substrate (29), was also highly expressed and phosphorylated in the tumours.  mTORC1 
activation mediated feedback also suppresses MAPK activity in Tsc2 null cells and inhibition 
of mTORC1 induces MAPK pathway activation (32). However, we found that the MAPK 
pathway was activated in Tsc2+/- mouse renal lesions.  Thus,  multiple negative feedback 
loops mediated by mTORC1 activation that are well documented in Tsc1 or Tsc2 null MEFs 
may be disrupted in renal tumours of Tsc2+/- mice. The discrepancies between our findings 
and previous reports may reflect differences in tissue origins and types of Tsc-associated 
tumours in Tsc2+/- mice, as well as differences in mechanisms underlying tumourigenesis 
between human and mouse. The genetic background of mice studied may also contribute to 
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the differences. In the current study mice were maintained in a balb/c background while the 
Tsc2+/- mice used by others were crossed to a 129/SvJae background (21, 31). Future work 
should extend our study to a thorough investigation of Akt/mTOR signalling in different 
types of TSC-associated tumours in both human and mouse. Constitutively activated Akt 
might be required for initiation and progression of Tsc-associated renal tumours in Tsc2+/- 
mice. Indeed Tsc1 or Tsc2 null MEF cells with operational negative feedback of Akt 
signalling have reduced tumorigenic potential whereas following expression of myr-Akt or 
PDGFRβ these cells have increased Akt activity and exhibit accelerated tumour growth in 
nude mice (20). Phosphorylation of Akt at T308 and S473 is required for its full activation. 
PDK1 phosphorylates Akt at T308 and the Rictor-containing mTOR complex (mTORC2) 
phosphorylates Akt at S473. In this study, phosphorylation of Akt at T308 appeared to be 
variable in renal lesions of Tsc2+/- mice and this indicates that basal phosphorylation of this 
site might be sufficient for Akt activation in these tumours.  Conditional complex gene 
knockouts (Tsc2-/-PDK1-/-or Tsc2-/-Rictor-/-) in mouse kidneys may help to verify the role of 
Akt activation in Tsc-associated renal tumourigenesis. 
 
     mTORC1 activation appears to mediate feedback inhibition of PI3K/Akt signalling 
through multiple mechanisms in Tsc1 or Tsc2 null MEF cells (Figure 9). One mechanism is 
S6K directed transcriptional repression of IRS1 and phosphorylation of IRS proteins at 
multiple serine sites that induces degradation of IRS proteins (16, 17). Consistent with this 
notion, we found that both Tsc2 null MEFs and renal tumours showed suppressed 
transcription of IRS1 and IRS2 and increased serine phosphorylation of IRS proteins. 
Unexpectedly, both IRS1 and IRS2 protein levels were increased in renal lesions whereas 
Tsc2 null MEFs had marked reduction in expression of these proteins. This may partly 
explain the lost feedback inhibition seen in renal tumours.  Recent studies have demonstrated 
12 
 
that mTORC1 exerts feedback inhibition of the PI3K and Erk-MAPK pathways through 
phosphorylation and stabilisation of Grb10 (18, 19). As expected, we found that Tsc2 null 
MEFs showed increased protein levels and phosphorylation of Grb10 which were sensitive to 
rapamycin. By contrast, in renal tumours Grb10 protein levels appeared to be slightly 
reduced, although phosphorylation of at least one serine site was highly increased. It is 
possible that reduced Grb10 may contribute to the active Akt signalling we observed in these 
tumours. In some cultured cancer cells and tumour samples,  mTORC1 inhibition abrogates 
feedback inhibition and activate PI3K/Akt signalling in an IGF1R dependent manner (33, 34). 
We found that IGF1R was consistently down regulated at transcriptional and protein levels in 
Tsc2 null MEFs and in renal tumours of Tsc2+/- mice. Taken together, our results suggest that 
in Tsc2+/- mouse renal tumours mTORC1 activation-associated feedback loops may be 
disrupted due to changes in expression, phosphorylation or stability of multiple pathway 
components (Figure 9).  Since IRS proteins have many candidate serine/threonine sites for 
phosphorylation, the patterns of phosphorylation of these proteins in Tsc1 or Tsc2 deficient 
tumours and MEF cells require further investigation in relation to the integrity of feedback 
loops. The ubiquitination machinery required for degradation of IRS proteins, for example 
cullin-RING E3 ubiquitin ligase 7 (35), should also be investigated in these tumours.  
 
     Rapamycin and its analogues have been used to treat various types of cancer and TSC–
associated tumours in preclinical models and in humans (24-27). However, no properly 
designed study has been reported using rapamycin or its analogues for prevention of Tsc-
associated renal tumours. This study provides the first proof of concept that Tsc-associated 
renal tumours are preventable by rapamycin. In addition to its inhibitory effects on mTORC1, 
prolonged treatment with rapamycin has been shown to inhibit Akt in tumour cells in a cell 
type dependent manner, and rapamycin-mediated inhibition of Akt may contribute to its 
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antitumor effect in vivo (36). While Akt signalling remains to be fully assessed in renal 
lesions of Tsc2+/- mice following rapamycin treatment, we have determined that long term 
treatment with rapamycin inhibits both mTORC1 and Akt in normal kidney tissues of Tsc2+/- 
mice. These results are consistent with previous findings by others that show an inhibitory 
effect of rapamycin on Akt in other normal tissues tested in wild type mice (37).  
 
     In conclusion, in contrast to previous studies, we have demonstrated that feedback 
inhibition of Akt signalling is lost in Tsc-associated renal lesions. Aberrant activation of both 
Akt and mTORC1 characterises Tsc-associated renal tumourigenesis in Tsc2+/- mice. By 
partially inhibiting the Akt/mTOR pathway, rapamycin appears sufficient to prevent Tsc-
associated tumours. Our data suggest that clinical trials should assess whether tumour 
manifestations in patients with TSC are also amenable to prevention by rapamycin or its 
analogues. It is notable that the high dose of rapamycin used in the current study caused 
initial poor weight gain and later weight loss (Supplemental Figure 11). It will be important 
to establish whether lower doses are also effective before translation to clinical trials.  
MATERIALS AND METHODS    
Animal procedures 
Animal procedures were performed in accordance with the UK Home Office guidelines and 
approved by the Ethical Review Group of Cardiff University. Tsc2+/- mice were described 
previously (22) and backcrossed to balb/c strain for over 10 times. Ear punches were used for 
DNA extraction and genotyping (22). For analysis of effect of rapamycin on molecular 
signalling in the kidneys by Western blot, 4 pairs of litter-mate Tsc2+/- mice  (2 months old) 
were randomly allocated into two groups (rapamycin and vehicle) and treated for 6 weeks 
with 5 mg/kg rapamycin or vehicle 5 times a week. Rapamycin (LC Laboratories, Woburn, 
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USA) was prepared at 2 mg/ml in vehicle solution (2.5% PEG-400, 2.5% Tween-80 and 
2.5% DMSO). These mice were humanely killed for tissue collection, and subsequent 
Western blot analysis. To test whether rapamycin could prevent renal tumourigenesis, 40 
Tsc2+/- mice were randomly divided into 2 treatment groups: vehicle and rapamycin. All 
treatments were performed from the age of one month until sacrifice at 8 months or 10 
months of age. Rapamycin was given by intra-peritoneal injection (i.p.) at 5 mg/kg 5 times a 
week initially but twice a week for the last 10 weeks due to concerns over weight loss. 
Rapamycin was given at 2.5 mg/kg once a week if rapid weight loss was observed. Mouse 
body weight was monitored once a week. At the end of treatment, animals were humanely 
killed for tissue collection, and subsequent histological and molecular analysis.  
Cell Culture  
Immortalised TP53-/-Tsc2+/+ and TP53-/-Tsc2-/- MEF cells were described previously (38). 
Wild type and Tsc1-/- MEF cells were prepared directly from viable E11 litter mates wild type 
and Tsc1-/- embryos derived from inbreeding of a Tsc1+/- mouse model (23). Cells were 
routinely grown in either serum-free DMEM or DMEM (Life Technologies Ltd, Paisley, UK) 
containing 10% FBS, 50 units/ml penicillin and 50 µg/ml streptomycin at 37°C in a 
humidified 5% CO2 incubator. 
Histology 
Assessment of mouse renal lesions was performed as described previously (30). Mouse 
kidneys were fixed in 10% buffered formalin saline (Thermo Scientific, Runcorn, UK) for 24 
hours. Fixed kidneys were processed and paraffin-embedded according to standard 
procedures. A series of 5 µm coronal kidney sections were prepared with or without 
interruption at 200 µm intervals from each kidney. They were haematoxylin and eosin (HE) 
stained and scanned to create virtual HE slides using an Aperio system 
(http://www.aperio.com/?gclid=CNXN-8by4aUCFcINfAods3eg1w). Virtual slides were used 
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for lesion quantification. Maximum cross-sectional whole area and cellular area of each renal 
lesion were measured respectively using ImageJ (http://rsbweb.nih.gov/ij). The assessment 
was conducted blindly with respect to treatment status. 
Immunohistochemistry (IHC)  
Antibodies against phosphorylated 4EBP1 (4EBP1 p-T37/46, 4EBP1 p-S65, 4EBP1 p-T70), 
Akt (pan), phosphorylated Akt (Akt p-T308, Akt p-S473, Akt p-T450), β-actin, GAPDH, 
phosphorylated Grb10 (p-S476), phosphorylated GSK3α (GSK3α p-S21), phosphorylated 
GSK3β (GSK3β p-S9),  IRS1, phosphorylated IRS1 (p-S302), IRβ, IGF1Rβ, phosphorylated 
Erk1/2 (p-T202/Y204), mTOR, S6, phosphorylated S6 (S6 p-S235/236), S6K and Tsc2 were 
supplied by Cell Signalling Technology (Danvers, USA). Antibodies against Cyclin D1, 
phosphorylated FOXO1A (FOXO1A p-S256), HIF1α, phosphorylated IRS2 (p-S731), Ki67 
and MUC1 were supplied by abcam (Cambridge, UK). Antiboies against phosphorylated 
eNOS (eNOS p-S1177), GLUT1, phosphorylated IKKα (IKKα p-T23), phosphorylated 
MDM2 (MDM2 p-S166), phosphorylated mTOR (mTOR p-S2448, mTOR p-S2481), 
phosphorylated RAF1 (RAF1 p-S259) and phosphorylated S6K (S6K p-T389) were supplied 
by Sigma-Aldrich (Dorset, UK). Antibody against IRS2 was supplied by Insight 
Biotechnology (Wembley, UK). Antibodies against Grb10 and phosphorylated Grb10 (p-
S501/503) were supplied by Millipore (U.K.) Limited (Watford, UK).  XPOSE Rabbit 
specific AP detection IHC kit (abcam, Cambridge, UK) or SignalStain Boost Rabbit specific 
IHC Detection Reagent (Cell Signalling Technology, Danvers, USA) was used to stain 
antigens. Briefly, paraffin-embedded mouse kidney sections were deparaffinised and 
rehydrated. Sections were boiled for 10 minutes in 10 mM sodium citrate buffer (pH 6.0). 
After cooling down in room temperature and 3 washes in TBST, sections were incubated in 
1.5% goat serum for 10 minutes at room temperature. Antigen staining was performed 




Primary antibodies used for IHC were also used for Western blot. Additional antibodies were 
purchased for Western blot including those against Akt1, phosphorylated Akt1 (Akt1 p-
S473), Akt2, Akt3, Erk1/2 and phosphorylated IGF1Rβ (p-Y1135/1136) (Cell Signalling 
Technology, Danvers, USA). Secondary antibody was horseradish peroxidise-conjugated 
antibody against rabbit (Cell Signalling Technology, Danvers, USA). Extracts of tumour 
samples, normal tissues or cultured cells were prepared using AllPrep DNA/RNA/Protein 
Mini Kit (QIAGEN Ltd-UK, Crawley, UK). Proteins were purified according to the kit 
supplier’s instruction. Twenty µg of protein per sample was separated on NuPAGE 4-12% 
Bis-Tris Gels (Life Technologies Ltd, Paisley, UK) and transferred onto Hybond ECL 
Membranes (GE Healthcare UK Ltd, Little Chalfont, UK ). Blots were analysed with ECL 
Select Western Detection Kit (GE Healthcare UK Ltd, Little Chalfont, UK) and signals were 
detected using Autochemi Imaging System (UVP, Upland, USA).  
Quantitative real time PCR (q-PCR) 
Total RNA was isolated from mouse kidney tissues, renal tumours or cultured cells using 
AllPrep DNA/RNA/Protein Mini Kit and TissueRuptor (QIAGEN Ltd-UK, Crawley, UK). 
One microgram RNA was used to synthesise cDNA in a 20 µl solution using qScript cDNA 
SuperMix (Quanta BioSciences, Inc., Gaithersburg, USA). A PCR reaction containing 1 µl 
cDNA, 2 µl 2.5 µM primer mix, 6.5 µl 2xPerfecta SYBR SuperMix (Quanta BioSciences, 
Inc., Gaithersburg, USA) and 3.5 µl water was performed in a 7500 Real Time PCR System 
(Life Technologies Ltd, Paisley, UK). PCR was cycled as 95°C for 3 minutes, 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute. The relative quantification of target transcripts 
was obtained after normalisation to HPRT. Primer sequences for real time q-PCR were: 
GAGCTTCCTGTGAAAGTGATG and GATTCGGTTCTTCCAGGTC for IGF1R; 
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CGCTCCAGTGAGGATTTAAG and GGTCTTCATTCTGCTGTGATG for IRS1; 
CTTCCTGTCCCATCACTTG and GTAGCGCTTCACTCTTTCAC for IRS2 and 
AGGGATTTGAATCACGTTTG and TTACTGGCAACATCAACAGG  for HPRT.  
 
Statistical Analysis 
Fisher's exact test was used to compare lesion numbers between vehicle and rapamycin 
treated mice.  Wilcoxon rank-sum (Mann-Whitney) test was performed to compare lesion 
size and lesion cellular areas between vehicle and rapamycin treated mice using the software 
Stata (version 11) (StataCorp LP, College Station, USA). P < 0.05 was considered to be 
statistically significant.        
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Figure 1  Analysis of Tsc2 expression in renal tumours of Tsc2+/- mice 
Kidney sections from Tsc2+/- mice of 10 months old were prepared and stained by IHC with 
an antibody against Tsc2. Representative kidney sections were presented showing lack of 
Tsc2 expression (a), reduced Tsc2 expression (b) and expression of Tsc2 (c) in renal lesions.  
Scale bars are 100.1 µm.  
Figure 2  mTOR signalling in kidney tissues and tumours of Tsc2+/- mice   
a. Tsc2+/- mice were sacrificed at 10 months of age. Kidney sections were prepared and 
stained with antibodies against total and phosphorylated mTOR at S2448 and S2481 by IHC. 
Scale bars are 100 µm. 
b.  Tsc2+/- mice were sacrificed at 10 months of age. Kidney sections were prepared and 
stained with antibodies against mTOR targets by IHC: total and phosphorylated S6K at T389, 
S6 at S235/236, and 4EBP1 at S65 and T37/46/70. Scale bars are100 µm. 
c. Tsc2+/- mice were sacrificed at 10 months of age. Proteins were prepared from paired 
normal kidney tissues (N) and kidney tumours (T) of the same mice, and used for Western 
blot to analyse expression of total mTOR, S6K, S6, and phosphorylation of mTOR at S2448 
and S2481, S6K at T389, S6 at S235/236, and  4EBP1 at S65 and T37/46. Genotyping for 
Tsc2 by PCR and expression analysis of Tsc2 by Western blot in kidney and tumour cells 
were shown in the bottom panel. 
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Figure 3 Akt signalling in kidney tissues and tumours of Tsc2+/- mice  
a. Tsc2+/- mice were sacrificed at 10 months of age. Kidney sections were prepared and 
stained with antibodies against total and phosphorylated Akt at T308, T450 and S473 by IHC. 
Scale bars for whole kidney sections are 5 mm and for the rest 100 µm. 
b.  Tsc2+/- mice were sacrificed at 10 months of age. Kidney sections were prepared and 
stained with antibodies against Akt targets by IHC: total HIF1α and GLUT1, and 
phosphorylated eNOS, MDM2, GSK3α, GSK3β, IKKα and RAF1. Scale bars are 100 µm. 
c. Tsc2+/- mice were sacrificed at 10 months of age. Proteins were prepared from paired 
normal kidney tissues (N) and kidney tumours (T) of the same mice, and used for Western 
blot to analyse expression of total Akt, Akt1, Akt2 and Akt3, and phosphorylation of Akt at 
s473, T450 and T308, Akt1 at s473, eNOS at s1177, MDM2 at s166, GSK3α at s21 and 
GSK3β at s9. Genotyping for Tsc2 by PCR and expression analysis of Tsc2 by Western blot 
in kidney and tumour cells were shown in the bottom panel. 
Figure 4 PKCα signalling in kidney tissues and tumours of Tsc2+/- mice 
a. Tsc2+/- mice were sacrificed at 10 months of age. Kidney sections were prepared and 
stained with antibodies against total and phosphorylated PKCα at T638 and S657 by IHC. 
Scale bars 100 µm. 
b. Tsc2+/- mice were sacrificed at 10 months of age. Proteins were prepared from paired 
normal kidney tissues (N) and kidney tumours (T) of the same mice, and used for Western 
blot to analyse expression of total and phosphorylated PKCα at T638 and S657. Genotyping 
for Tsc2 by PCR and expression analysis of Tsc2 by Western blot in kidney and tumour cells 
were shown in the bottom panel. 
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 Figure 5 Comparison of mTOR/Akt feedback signalling between renal tumours of 
Tsc2+/- mice and cultured Tsc2-/- MEF cells 
Tsc2+/- mice were sacrificed at 10 months of age. Proteins were prepared from paired normal 
kidney tissues (N) and kidney tumours (T) of the same mice (left panel). Proteins were also 
prepared from immortalised TP53-/-Tsc2+/+ or TP53-/-Tsc2-/-  MEF cells which were grown in 
serum free DMEM for 16 hours (right panel). Proteins were then used for Western blot to 
analyse expression of total IRS1, IRS2, Grb10, IRβ, IGF1Rβ, Erk1/2, and GAPDH, and 
phosphorylation of IRS1 at S302, IRS2 at S731, Grb10 at S476 and S501/503, IGF1Rβ at 
Y1135/1136, Erk1/2 at T202/Y204, Akt at S473 and S6 at S235/236. 
Figure 6   Analysis of expression and phosphorylation of IRS and Grb10 proteins in 
renal tumours of Tsc2+/- mice 
Tsc2+/- mice were sacrificed at 10 months of age. Kidney sections were prepared and stained 
by IHC with antibodies against total IRβ, IGF1Rβ, IRS1, IRS2 and Grb10, and 
phosphorylated IRS1 at S302, IRS2 at S731 and Grb10 at S476. Scale bars are 100 µm. 
Figure 7 Inhibition of Akt/mTOR signalling by rapamycin in kidney tissues of Tsc2+/- 
mice 
Four pairs of litter-mate Tsc2+/- mice were randomly allocated into two groups and treated for 
6 weeks with 5 mg/kg rapamycin or vehicle 5 times a week. Mice were sacrificed and one 
kidney each mouse was used for protein preparation and Western blot. Western blots were 
probed with antibodies against phosphorylated Akt at T308 and S473, GSK3β at S9, eNOS at 
S1177, MDM2 at S166, mTOR at S2448 and S2481, and S6 at S235/236, and total 4EBP1. 
Figure 8 Prevention of renal tumourigenesis by inhibition of Akt/mTOR signalling with 
rapamycin in Tsc2+/- mice 
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a. Prevention of renal tumourigenesis.  Tsc2+/- mice were treated from one month old until 
sacrifice at the age of 8 months (top panel) (vehicle, n=10; rapamycin, n=9) or 10 months 
(bottom panel) (vehicle, n=10; rapamycin, n=10). Dosages are described in Methods. Kidney 
sections were prepared for histological assessment of treatment effect. Lesion number and 
size (area) as well as lesion cellular area were compared for mice sacrificed at the age of 8 
and 10 months respectively. Horizontal bars indicate a median. All the mice treated with 
vehicle developed multiple lesions at both ages. In contrast, only two microscopic cysts were 
seen in one of the rapamycin treated mice at the age of 8 months. For detailed statistical 
analysis see Supplemental Table 3. 
b. Inhibition of Akt/mTOR signalling. Tsc2+/- mice were treated as described above. Kidney 
sections were prepared for IHC analysis using antibodies against phosphorylated S6 at 
S235/236,  4EBP1 at S65, Akt at T308 and S473,  eNOS at S1177 and MDM2 at S166.   
Figure 9 Model for loss of feedback inhibition of PI3K/Akt and Ras/Erk signaling in 
Tsc1-/- or Tsc2-/- renal tumour cells    
On the left is a representation of a MEF cell lacking functional Tsc1 or Tsc2.This shows 
mTORC1 activation-mediated feedback inhibition of PI3K/Akt and Ras/Erk signalling 
through multiple mechanisms including serine phosphorylation of IRS proteins by 
mTOR/S6K1 and their subsequent degradation. Solid red lines show feedback via established 
mechanisms; broken red lines show feedback where precise mechanisms remain to be 
determined. Activated pathway components are shown in dark green and inhibited 
components in grey. On the right is a representation of a Tsc1-/- or Tsc2-/- renal tumour cell.  
“X” indicates possibly disrupted feedback loops.  The activation status of pathway 
components in light green requires further study as do their relationships ( broken black 
lines). Additional genetic and epigenetic changes may contribute to disruption of feedback 
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loops in tumour cells, leading to stabilisation of IRS proteins, increased Akt activity and Erk 
activation.     
  









